Continuous infusion (24 μg/kg/hr) of wt-APC for 96 h in severe sepsis patients was associated with an increased risk of bleeding in large phase III clinical trials [6], and wt-APC is currently no longer available for clinical use. The gene discussed is APC; the disease is Sepsis.